Content
CSL Ltd. (ASX) Elliott Wave Technical Analysis - March 18, 2024
Article By:
Peter Mathers
Read
Monday, March 18, 2024 3:03 AM EDT
Our technical analysis today updates the Australian Stock Exchange (ASX) CSL Ltd. shares. We have identified a triangle correction pattern, indicating the potential for further decline.
Week In Review: Under Pressure From US Congress, WuXi AppTec Resigns From BIO
Article By:
ChinaBio® Today
Read
Saturday, March 16, 2024 2:40 PM EDT
BIO, the global lobbying organization for biotechnology firms, forced WuXi AppTec to leave the group due to pressure from the US Congress. Also, Boehringer Ingelheim acquired an option to license drug candidates that treat symptoms of schizophrenia.
The Generic Drugs Antitrust Case
Article By:
Timothy Taylor
Read
Friday, March 15, 2024 11:00 PM EDT
Imagine that in the market for generic drugs, a group of companies form a cartel to raise prices on the products controlled by their group. What pattern might you expect to see for the prices of drugs?
In this article: TEVA
In A Free Market, Drugs Are Cheap, Government Policies Make Them Expensive
Article By:
Dean Baker
Read
Tuesday, March 12, 2024 5:47 AM EDT
We will spend well over $600 billion this year on drugs. These drugs would likely cost less than $100 billion in a free market.
Current Analysis: Elekta AB (EKTAF)
Article By:
Fredrik Arnold
Read
Sunday, March 10, 2024 7:07 PM EDT
The company's installed base of more than 5,000 linear accelerators, GammaKnife and Unity platforms, and software is used in more than 6,000 hospitals globally.
In this article: EKTAF
What A Trip: Psychedelic Medicine Company MindMed Shares Rocket 50% After Positive Data
Article By:
Tyler Durden
Read
Sunday, March 10, 2024 1:00 PM EDT
Shares of clinical stage biopharmaceutical company MindMed were heavily monitored on Friday after the stock rocketed higher during Thursday's cash session by more than 51% on more than 30x the company's average volume.
In this article: MNMD
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Article By:
Zacks Investment Research
Read
Saturday, March 9, 2024 4:00 PM EDT
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the year.
Week In Review: EurekaBio Raises $40 Million To Support Lentiviral Vector Platform
Article By:
ChinaBio® Today
Read
Saturday, March 9, 2024 2:20 PM EDT
Shenzhen EurekaBio closed a $40 Series B+ funding to support the commercialization of its EuLV Lentiviral Vector Production System, a technology that the company believes could transform large-scale production of lentiviral vectors.
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
Article By:
Zacks Investment Research
Read
Saturday, March 9, 2024 1:40 PM EDT
This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung cancer medicine, Rybrevant, for first-line use.
CERo Therapeutics, Inc. Announces Publication Of Preclinical Research Supporting The Use Of Its Clinical Candidate CER-1236 To Treat AML Patients
Article By:
Business Wire
Read
Thursday, March 7, 2024 7:00 AM EDT
The paper details preclinical studies by CERo analyzing its lead clinical candidate CER-1236 in targeting Acute Myelogenous Leukemia (AML) tumor cells from human patients, and the candidate’s killing effects on these tumor cells.
Landos Biopharma - Investor Like It Better Than Analysts
Article By:
Jim Van Meerten
Read
Thursday, March 7, 2024 4:07 AM EDT
Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class therapeutics for patients with autoimmune disease.
In this article: LABP
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Article By:
Lorimer Wilson
Read
Monday, March 4, 2024 12:41 AM EDT
Grand View Research says the global "AI in drug discovery" market should expand at a CAGR of 30% between now, and 2030 which Morgan Stanley believes will lead to 50 novel therapies over the next decade, with annual sales in excess of $50 billion.
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
Article By:
ChinaBio® Today
Read
Saturday, March 2, 2024 2:00 PM EDT
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global rights for Roxadustat to FibroGen.